Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VCAP + AMP + VECP
- Development stage
- Phase 3
- Lead developer
- National Cancer Center Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
VCAP + AMP + VECP is a multi-agent chemotherapy regimen used as front-line therapy for adult T-cell leukemia-lymphoma (ATLL) associated with human T-lymphotropic virus type I. The regimen consists of three alternating components: - VCAP: vincristine, cyclophosphamide, doxorubicin (adriamycin), and prednisone - AMP: doxorubicin (adriamycin), ranimustine (MCNU), and prednisone - VECP: vindesine, etoposide, carboplatin, and prednisone The mechanism of action is based on combined cytotoxic activity against malignant T-cells, with each component targeting different cellular pathways primarily through microtubule disruption, DNA alkylation, and inhibition of topoisomerase. The regimen has shown superior outcomes to CHOP in aggressive ATLL in some risk groups, especially in Japan, and is used as an induction therapy.
- Other names
- VCAP-AMP-VECP regimen
02
Targets
DNAGR (Glucocorticoid receptor)TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on VCAP + AMP + VECP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VCAP + AMP + VECP.